查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019357

全球呼吸道病毒疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Respiratory Virus Vaccines Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計呼吸道病毒疫苗市場將從 2025 年的 108.2 億美元成長到 2034 年的 222.2 億美元，2026 年至 2034 年的複合年成長率為 8.32%。

全球呼吸道病毒疫苗市場經歷了顯著成長，尤其是在新冠肺炎疫情爆發後，疫情凸顯了接種呼吸道感染疾病的重要性。針對流感、呼吸道融合細胞病毒（RSV）和冠狀病毒的疫苗需求正在增加。隨著世界各國政府和醫療機構將疫苗接種計畫列為優先事項，全球疫苗接種率和覆蓋率正在增加。

成長要素包括呼吸道感染疾病率上升、公眾意識增強以及mRNA和重組疫苗等技術的進步。製藥公司正致力於研發能夠抵禦多種呼吸道病毒的聯合疫苗。此外，為應對季節性疫情和全球疫情而採取的措施也推動了疫苗研發和生產能力的持續投入。

未來，得益於持續的創新和全球疫苗接種策略，市場預計將強勁成長。通用疫苗和無針注射系統的研發有望提升接種的便利性和遵守用藥。開發中國家醫療保健覆蓋範圍的擴大和政府投入的增加，預計將進一步推動市場成長，並確保更好地抵禦新出現的和現有的呼吸道病毒。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球呼吸道病毒疫苗市場：依類型分類

  • 市場分析、洞察與預測
  • 去活化疫苗
  • 減毒活病毒疫苗
  • 重組疫苗

第5章 全球呼吸道病毒疫苗市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 肌肉內部
  • 鼻內
  • 皮下

第6章 全球呼吸道病毒疫苗市場：依適應症分類

  • 市場分析、洞察與預測
  • 流感
  • 麻疹
  • 腮腺炎和德國德國麻疹
  • 冠狀病毒感染疾病（COVID-19）

第7章 全球呼吸道病毒疫苗市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第8章 全球呼吸道病毒疫苗市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫生辦公室
  • 醫院
  • 診所
  • 藥局和零售店

第9章 全球呼吸道病毒疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和分銷通路合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Sanofi
    • AstraZeneca
    • Merck & Co. Inc
    • GlaxoSmithKline PLC
    • Serum Institute Of India Pvt. Ltd
    • Moderna Inc
    • Bavarian Nordic
    • SINOVAC
    • INOVIO Pharmaceuticals
簡介目錄
Product Code: VMR11215029

The Respiratory Virus Vaccines Market size is expected to reach USD 22.22 Billion in 2034 from USD 10.82 Billion (2025) growing at a CAGR of 8.32% during 2026-2034.

The global respiratory virus vaccines market has experienced significant growth, especially following the COVID-19 pandemic, which highlighted the importance of immunization against respiratory infections. Vaccines targeting influenza, respiratory syncytial virus (RSV), and coronaviruses are increasingly in demand. Governments and healthcare organizations are prioritizing vaccination programs, leading to higher adoption rates and expanded immunization coverage worldwide.

Major growth drivers include rising incidences of respiratory infections, increased public awareness, and advancements in vaccine technologies such as mRNA and recombinant platforms. Pharmaceutical companies are focusing on developing combination vaccines that provide protection against multiple respiratory viruses. Additionally, seasonal outbreaks and pandemic preparedness initiatives are encouraging continuous investment in vaccine research and production capabilities.

In the future, the market is poised for robust expansion due to ongoing innovation and global vaccination strategies. The development of universal vaccines and needle-free delivery systems is expected to enhance convenience and compliance. Expanding healthcare access in developing countries and increasing government funding will further drive growth, ensuring better protection against emerging and existing respiratory viruses.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Inactivated/Killed
  • Live-attenuated
  • Recombinant

By Route of Administration

  • Intramuscular
  • Intranasal
  • Subcutaneous

By Indication

  • Influenza
  • Measles
  • Mumps & Rubella
  • Coronavirus Disease (COVID-19)

By Age Group

  • Pediatric
  • Adults

By End User

  • Physician Offices
  • Hospitals
  • Clinics
  • Pharmacies/Stores

COMPANIES PROFILED

  • Sanofi, AstraZeneca, Merck Co Inc, GlaxoSmithKline PLC, Serum Institute of India Pvt Ltd, Moderna Inc, Bavarian Nordic, SINOVAC, INOVIO Pharmaceuticals
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Inactivated/Killed Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Live-attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Recombinant Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Indication
  • 6.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Measles Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Mumps & Rubella Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.5. Coronavirus Disease (COVID-19) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Age Group
  • 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY END USER 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast End User
  • 8.2. Physician Offices Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.5. Pharmacies/Stores Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Type
    • 9.2.2 By Route Of Administration
    • 9.2.3 By Indication
    • 9.2.4 By Age Group
    • 9.2.5 By End User
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Type
    • 9.3.2 By Route Of Administration
    • 9.3.3 By Indication
    • 9.3.4 By Age Group
    • 9.3.5 By End User
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Type
    • 9.4.2 By Route Of Administration
    • 9.4.3 By Indication
    • 9.4.4 By Age Group
    • 9.4.5 By End User
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Type
    • 9.5.2 By Route Of Administration
    • 9.5.3 By Indication
    • 9.5.4 By Age Group
    • 9.5.5 By End User
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Type
    • 9.6.2 By Route Of Administration
    • 9.6.3 By Indication
    • 9.6.4 By Age Group
    • 9.6.5 By End User
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RESPIRATORY VIRUS VACCINES INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Sanofi
    • 11.2.2 AstraZeneca
    • 11.2.3 Merck & Co. Inc
    • 11.2.4 GlaxoSmithKline PLC
    • 11.2.5 Serum Institute Of India Pvt. Ltd
    • 11.2.6 Moderna Inc
    • 11.2.7 Bavarian Nordic
    • 11.2.8 SINOVAC
    • 11.2.9 INOVIO Pharmaceuticals